CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cell Therapy Catapult Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cell Therapy Catapult Limited
12th Floor Tower Wing, Guy's Hospital
Great Maze Pond
Phone: +44 (0) 203 728 9500p:+44 0 203 728 9500 London, SE1 9RT  United Kingdom
Business Summary
Cell Therapy Catapult, established in 2012, is a not for profit company with the goal of developing, delivering and commercializing cell and gene therapy. The Company's mission is to grow the industry in the UK to substantial and sustainable levels by: Accelerating commercialization of innovation from research; Complementing industry and academia with unique technical facilities and expertise; Innovating through collaborations with academic and industry networks; and Facilitating growth of the UK ecosystem by working with industry, the research base, Government, the NHS, industry associations and international organizations. The Company operates through two subsidiaries: CGT Catapult Manufacturing Innovation Centre Ltd. and Cell Therapy Catapult Services Ltd.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20203/31/2020-----

Industries
SIC Code Description
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman, Board of Directors Dr JohnBrown, CBE, FRSE
Chief Executive Officer MatthewDurdy
Chief Financial Officer BrianCollins

Business Names
Business Name
CGT Catapult Manufacturing Innovation Centre Ltd.
Chimeric Therapeutics Ltd.

General Information
Email Address: info@ct.catapult.org.uk


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 22, 2022